Effect of fenofibrate in combination with urate lowering agents in patients with gout

You-Hyun Lee, Chan-Hee Lee, Jisoo Lee, You-Hyun Lee, Chan-Hee Lee, Jisoo Lee

Abstract

Background: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout.

Methods: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbromarone) for > or = three months without acute attack for the most recent one month before participating. All patients were being treated with established doses of urate lowering agents without modification throughout the study. Clinical and biochemical assessments including serum uric acid, creatinine, liver function test and fasting serum lipid were measured at (1) baseline (2) after two months of fenofibrate treatment and (3) two months after fenofibrate was withdrawn.

Results: Serum uric acid was lowered by 23% after two months of fenofibrate treatment (6.93 +/- 2.16 vs. 5.22 +/- 1.16 mg/dL; p = 0.016). Triglyceride levels were also reduced after fenofibrate treatment (p = 0.001). However, this effect was reversed after the withdrawal (p = 0.002) of the drug. Alkaline phosphatase was reduced after fenofibrate treatment (p = 0.006), but increased 21% after the withdrawal of the drug (p = 0.002). By contrast, serum levels of high density lipoprotein and creatinine were increased 9% (p = 0.018) and 12% (p = 0.006), respectively; however, both levels were significantly decreased to the baseline levels upon withdrawal of fenofibrate.

Conclusions: Fenofibrate can effectively reduce uric acid levels in addition to its known hypolipidemic effect. Fenofibrate may be used as a potential urate lowering agent in patients with gout, especially in those with coexisting hyperlipidemia.

Figures

Figure 1
Figure 1
Effect on (A) uric acid (B) triglyceride (C) alkaline phosphatase (ALP) with and without fenofibrate therapy
Figure 2
Figure 2
Effect on (A) high density cholesterol (B) creatinine with and without fenofibrate therapy

References

    1. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep. 2002;4:270–274.
    1. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol. 2003;30:2245–2251.
    1. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96) J Rheumatol. 2001;28:1640–1646.
    1. Yoo B. Serum uric acid levels in Korean adult population and their correlates. J Korean Rheum Assoc. 1995;2:60–68.
    1. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–2406.
    1. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight. Br J Rheumatol. 1994;33:731–734.
    1. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997;54:615–633.
    1. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980;20:560–564.
    1. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye AE. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003;42:321–325.
    1. Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y, Fuse M, Takeo C, Saito Y. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb. 2004;11:335–340.
    1. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol. 1980;20:560–564.
    1. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effect of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62:572–575.
    1. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effect of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism. 1988;37:217–220.
    1. de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther. 1999;66:166–172.
    1. Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 1993;42:839–842.
    1. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004;10:894–898.
    1. Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M. Effect of various fibrates on serum alkaline phosphatase activity. Atherosclerosis. 2002;165:187–188.
    1. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin+fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol. 1999;69:237–244.
    1. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis. 1998;32:917–933.
    1. Schmidt MI, Watson RI, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism. 1996;45:699–706.
    1. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Higashino K. Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridemia. Ann Rheum Dis. 1995;54:351–354.
    1. Collantes Estevez E, Pineda Priego M, Anon Barbudo J, Sanchez Guijo P. Hyperuricemia-hyperlipidemia association in the absence of obesity and alcohol abuse. Clin Rheumatol. 1990;9:28–31.
    1. Tinahones JF, Perez-Lindon G, C-Soriguer FJ, Pareja A, Sanchez-Guijo P, Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab. 1997;82:1188–1191.
    1. Ledwith BJ, Pauley CJ, Wagner LK, Rokos CL, Alberts DW, Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem. 1997;272:3707–3714.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi